RxDoctor Payments Data

Mehjabeen Alam, MD

Internal Medicine · Matamoras, PANPI 1417906744

Payments from drug & device makers

$2,177in general payments, 2019–2025

Across 141 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$366
  • Novo Nordisk$330
  • Lilly USA, LLC$329
  • AstraZeneca$209
  • Pfizer$180
  • E.r. Squibb & Sons, L.L.C.$158
  • plus $605 from 10 others

What the payments were for

  • Food & beverage$2,177100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,177 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$135,668
Medicare patients
357
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate77$98,447
OzempicSemaglutide52$62,985
JardianceEmpagliflozin54$55,553
TrulicityDulaglutide28$44,733
MounjaroTirzepatide29$37,496
EliquisApixaban24$31,637
XareltoRivaroxaban39$22,935
JanumetSitagliptin Phos/Metformin Hcl12$17,277
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$17,020
TradjentaLinagliptin11$15,412
Tresiba Flextouch U-100Insulin Degludec17$14,194
FarxigaDapagliflozin Propanediol13$12,458
Tresiba Flextouch U-200Insulin Degludec12$12,084
Breo ElliptaFluticasone/Vilanterol25$10,645
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$108$115,72489 claims
Lilly USA, LLCTrulicity, Mounjaro$329$82,22957 claims
Boehringer IngelheimJardiance, Tradjenta$93$70,96565 claims
Novo NordiskOzempic$330$62,98552 claims
PfizerEliquis$180$31,63724 claims
GSKTrelegy Ellipta, Breo Ellipta$366$27,66548 claims
Johnson & JohnsonXarelto$110$22,93539 claims
AstraZenecaFarxiga, Bevespi Aerosphere$209$17,33224 claims
AbbVieSynthroid$23$1,01423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Matamoras

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →